PLRX logo

PLIANT THERAPEUTICS INC

PLRXNASDAQ
๐Ÿ† #4308 by market capUS Equity
$0.59โ–ผ $0.03 (โˆ’4.56%)
Market closed ยท at close
๐Ÿ””
Track PLRX
Get earnings, price moves & breaking news on Telegram
Track
24hโ–ผ 4.6%
7dโ–ผ 14.9%
14dโ–ผ 26.5%
30dโ–ผ 31.5%
ytdโ–ผ 51.0%
1yโ–ผ 61.5%
๐ŸฆMarket Cap
$37M
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
โ€”
๐Ÿ“ŠGross Margin
โ€”
๐Ÿ’ตFCF Margin
โ€”
โš–๏ธP/S Ratio
7.3x
Fair
Otter Score
โ€”
Insufficient data

Trading Snapshot

Day Range
$0.58 โ€“ $0.60
52-Week Range
$0.57 โ€“ $1.67
Volume (shares)
28,011
Avg Volume (shares)
โ€”
Shares Outstanding
61.9M
Next Earnings
โ€”

Fundamentals Snapshot

Annual Revenue
โ€”
Last Q Revenue
โ€”
P/E Ratio
โ€”
P/S Ratio
7.3x
EPS (TTM)
$-2.43
Dividend Yield
โ€”
PLRX logo

PLIANT THERAPEUTICS INC

PLRX
Financial Trends

Financial history unavailable.

StockOtter ยท stockotter.space

About PLIANT THERAPEUTICS INC

Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avรŸ6 and avรŸ1 integrins, which is currently progressing through three distinct Phase 2a clinical trials. The company's pipeline also includes PLN-1474, a small-molecule selective inhibitor of avรŸ1, which has successfully completed its Phase 1 clinical assessment for treating liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Furthermore, Pliant is nurturing two additional integrin-based initiatives in preclinical development: one focused on oncology, and another involving an allosteric agonistic monoclonal antibody designed to act upon an undisclosed integrin receptor for the treatment of various muscular dystrophies, including Duchenne muscular dystrophy. Founded in 2015, Pliant Therapeutics, Inc. maintains its corporate headquarters in South San Francisco, California.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Insufficient data
โ€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.